MET and neoplasm: In previous studies, a fluorescence-labeled compound, which could bind to tumor-specific molecules, such as vascular endothelial growth factor (VEGF) [9, 10], epidermal growth factor receptor (EGFR) [11], colon cancer specific protein-2 (CCSP-2) [12], endothelial A receptor (ETAR) [13], and c-Met [14] was developed to detect colon cancer.